BAM
ADMA icon

Blueshift Asset Management’s ADMA Biologics ADMA Stock Holding History

Blueshift Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,269
Closed -$176K – 386
2024
Q4 		$176K Buy
+10,269
New +$193K 0.06% 347

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

Blueshift Asset Management's ADMA Position: Q1 2025 in Review

Blueshift Asset Management sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 10,269 shares — an estimated $176K sold.

Blueshift Asset Management first reported a position in ADMA in Q4 2024 and held it in 1 quarter. The position peaked at $176K in Q4 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

  • Blueshift Asset Management reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
  • Blueshift Asset Management sold 10,269 ADMA Biologics shares in Q1 2025, an estimated $176K.
  • Blueshift Asset Management first reported a position in ADMA Biologics in Q4 2024 and held it in 1 quarter.
  • Blueshift Asset Management's ADMA Biologics position peaked at $176K in Q4 2024.
  • 347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on Blueshift Asset Management's 13F filing for Q1 2025, filed 8 May 2025.